Bictegravir 1611493-60-7
Descriptio
Bictegravir nova est, potens inhibitor HIV-1 integrae cum IC50 7.5 nm.
In vitro
Bictegravir (BIC) vetat activitatem in acia transferre cum IC50 inter 7.5± 0.3 nM.Relativum ad suum inhibitionis trans- litus activitatem, Bictegravir multo debilior est inhibitor of 3.-processing actio HIV-I IN, cum IC50 de CCXLI±51 nM.Bictegravir auget cumulum 2-LTR circulorum ~5-plicarum relativum ad ludibrium tractatum imperium et quantitatem productorum integrationis authenticae in cellulis infectis per 100-duplicem reducit.Bictegravir potenter vetat replicationem HIV-1 in utraque MT-2 et MT-4 cellularum cum EC50s 1.5 et 2.4 nM, respective.Bictegravir effectus antivirales potentes exhibet lymphocytes tum primarios CD4+ T et macrophages monocyto-ectae, cum EC50s 1.5.±0.3 nM et 6.6 "±4.1 nM, respective, quae cum valoribus in lineis T-cellulis habitis comparantur[1].
MCE independenter subtilitatem horum methodorum non confirmavit.Tantum referendi sunt.
| NCT Number | Sponsor | Conditio | Satus Date | Phase |
| NCT03998176 | Universitas Nebraska|Gilead Sciences | HIV-1-infectio | October 9, 2019 | Phase 4 |
| NCT03789968 | Thomas Jefferson University|University of Maryland, College Park|University of Maryland, University Health | | HIV+AIDS | Septembris 1, 2019 | |
| NCT04249037 | University of Colorado, Denver|Gilead Sciences | HIV+AIDS | Martii 1, 2020 | Non pertinet |
| NCT04132674 | Vancuverium morbis infectivis Centre | Humana immunitas Virus I Infectio|Drug Use | November 26, 2018 | Phase 4 |
| NCT04054089 | Cristina Mussini Universitas Mutinensis et Regii Lepidi | HIV Infectiones | September 2019 | Phase 4 |
| NCT04155554 | Azienda Ospedaliera Universitaria Senese | Catholic University of the Holy Heart | Ospedale Policlinico San Martino | | HIV-1-infectio | Die 29 Ianuarii, 2020 | Phase 3 |
| NCT02275065 | Gilead Sciences | HIV-1 Infectio | October 2014 | Phase 1 |
| NCT03711253 | Universitas Southern California | Acute HIV Infectio | October 14, 2019 | Phase 4 |
| NCT02400307 | Gilead Sciences | HIV | April 17, 2015 | Phase 1 |
| NCT03499483 | Fenway Community Health | HIV Prevention | Die 24 mensis Ianuarii, 2019 | Phase 4 |
| NCT03502005 | Mediterranei Research Group, Inc.|Gilead Sciences | De Viris Illustribus Humanis | Martii 1, 2018 | Phase 4 |
Chemical structure
Rogatio18Qualitas Constantia Aestimatio inceptis quae probaverunt4, et6incepta approbantes.
Provectus qualitas internationalis administrandi ratio solidum fundamentum venditio posuit.
Qualitas vigilantia percurrit totum vitae cyclum producti, ut qualitatem et therapeuticum effectum curet.
Negotiis professionalibus regularibus turmas sustinet qualitatem postulatorum in applicatione et adnotatione.
Korea Countec Bottled Packaging linea
Taiwan CVC Bottled Packaging Line
Italia CAM Board Packaging Line
German Fette Compacting Machine
Iaponia Viswill Traba Detector
DCS Control Room
